CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
pneumonia (CAP) or moderate / severe Coronavirus Disease 2019 (COVID-19) pneumonia.Other objectives are to determine pharmacokineti...
Phase 3
Paris, France and 58 other locations
seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.It also contains a sub-study to enroll patients with severe COVID...
Phase 3
Créteil, Ile-de-France, France and 66 other locations
known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.The aim of the Phase I/III study (Parent Study) will -...
Phase 2, Phase 3
Paris cedex 10, France and 214 other locations
The COVID-19 pandemic is a novel medical challenge, particularly because of the systemic nature of this disease. Indeed, COVID...
Paris, France
NEUROCOVID is a prospective multicenter study comparing the proportion of patients with SARS-CoV-2 viral RNA at the level of the olfactory clefts in...
Paris, France and 1 other location
One of the current health challenges in the face of the COVID-19 pandemic that started in Wuhan in 2019, and still responsible for ...
Paris, France
Currently, there is no approved treatment for COVID-19 in France, either for the acute phase, nor for the late chronic phase. the i...
Phase 3
Paris, France
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants...
Phase 2
Paris 15, France and 35 other locations
The main aim of this study is to check if there are side effects from BAX 888 and to determine the dose of BAX 888 for treating severe hemophilia A i...
Phase 1, Phase 2
Le Kremlin Bicêtre cedex, Val De Marne, France and 25 other locations
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...
Phase 3
Paris, Cedex, France and 246 other locations
Clinical trials
Research sites
Resources
Legal